Condition: Atypical Hemolytic Uremic Syndrome · Sponsor: AstraZeneca
This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center Study Information Center · +118772409479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Gdansk, Poland | Not Yet Recruiting |
| Research Site | Katowice, Poland | Not Yet Recruiting |
| Research Site | Katowice, Poland | Recruiting |
| Research Site | Krakow, Poland | Not Yet Recruiting |
| Research Site | Lodz, Poland | Not Yet Recruiting |
| Research Site | Poznan, Poland | Not Yet Recruiting |
| Research Site | Poznan, Poland | Recruiting |
| Research Site | Warsaw, Poland | Not Yet Recruiting |
| Research Site | Warsaw, Poland | Recruiting |
| Research Site | Wroclaw, Poland | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07399730